Table 3 Baseline characteristics between patients with thrombosis who underwent cytoreductive nephrectomy (CN) and did not undergo CN.
Covariate | Full sample (n = 64) | No surgery (n = 18) | Cytoreductive nephrectomy (n = 46) | p-valuea |
|---|---|---|---|---|
Age | 0.087 | |||
Median (Q1, Q3) | 58.6 (50.0,66.4) | 61.4 (55.1,69.6) | 57.1 (48.6,63.8) | |
Gender | 0.53 | |||
Female (n, %) | 15 (23) | 3 (17) | 12 (26) | |
Male (n, %) | 49 (77) | 15 (83) | 34 (74) | |
Histology | 0.11 | |||
Clear cell (n, %) | 44 (69) | 14 (78) | 30 (65) | |
Non-clear cell (n, %) | 19 (30) | 3 (17) | 16 (35) | |
Unclassified tumour (n, %) | 1 (2) | 1 (6) | 0 (0) | |
No of metastatic sites | ||||
>1 (n, %) | 48 (75) | 15 (83.3) | 33 (68.8) | 0.52 |
1 (n, %) | 16 (25) | 3 (16.7) | 13 (27.1) | |
KPS | 0.61 | |||
<80 (n, %) | 24 (37.5) | 5 (27.8) | 10 (21.7) | |
>=80 (n, %) | 40 (62.5) | 13 (72.2) | 36 (78.3) | |
IMDC category | 0.55 | |||
Favourable (n, %) | 3 (5) | 0 (0) | 3 (7) | |
Intermediate/poor (n, %) | 61 (95) | 18 (100) | 43 (93) | |
Mayo classification | 0.4 | |||
0 (n, %) | 31 (50) | 13 (72.2) | 20 (43) | |
I (n, %) | 7 (11) | 0 (0) | 7 (15) | |
II (n, %) | 9 (15) | 2 (12) | 7 (15) | |
III (n, %) | 11 (18) | 2 (12) | 9 (20) | |
IV (n, %) | 4 (6) | 1 (6) | 3 (7) | |
Systemic therapy | ||||
Sunitinib (n, %) | 48 | 14 | 34 | |
Sorafenib (n, %) | 5 | 1 | 4 | |
Pazopanib (n, %) | 2 | 2 | 0 | |
Chemotherapy (n, %) | 3 | 1 | 2 | |
Nivolumab-ipilimumab (n, %) | 5 | 0 | 5 | |
Bevacizumab Erlotinib (n, %) | 1 | 0 | 1 | |
